C3 Jian, Inc., a private company focused on providing improved oral health care, announced today that it has successfully completed the initial Phase 2 clinical trial for its novel drug, C16G2. The company’s drug targets the specific elimination of Streptococcus mutans, the acid-producing bacterium associated with dental caries or tooth decay.

(Visited 7 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *